Product Detail
Paliperidone palmitate
Paliperidone palmitate API
Stock Status: In Stock
Login to view price
Live
For Research & Analytical Purposes. Not for Personal use.
Category
API
API Family
Paliperidone palmitate
Storage
Store at refrigerator (2-8°C) for long term storage
Hazard Information
Refer MSDS for accurate information.
Paliperidone palmitate Product Information
Paliperidone palmitate is listed under API. It is associated with Paliperidone palmitate and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-O-02155.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
Paliperidone palmitate
CAS No.
199739-10-1
CAT No.
CS-O-02155
Molecular Formula
C39H57FN4O4
Molecular Weight
664.91
Category
API Family
Storage Condition
Store at refrigerator (2-8°C) for long term storage
SMILES
CCCCCCCCCCCCCCCC(OC1CCCN(C1=NC(C)=C2CCN3CCC(C4=NOC5=C4C=CC(F)=C5)CC3)C2=O)=O
IUPAC Name
3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl palmitate
Purity by HPLC
Not less than 95%
Hazard Compound
Refer MSDS for accurate information.
Description
Overview
Paliperidone Palmitate is a benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.
Synonyms
9-Hydroxyrisperidone Palmitate; Invega Sustenna
Application Notes
Paliperidone Palmitate is a benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.
References
"Hough; D, et al,: Prog, Neuro-pschophamcol, Biol, Psch,; 33; 1022 (2009); Samtani; M,N, et al,:clin, Pharmcokin,; 48; 585 (2009); Nasrallah; H,A, et al,: Neuropschopharmcology; 35; 2072 (2010);"
